| Diabetes Mellitus, Non-Insulin-Dependent

Ozempic vs Welchol

Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.

Deep comparison between: Ozempic vs Welchol with Prescriber.AI

AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.

Safety signalsWelchol has a higher rate of injection site reactions vs Ozempic based on FDA-approved prescribing information

Coverage gaps3 major payers require step therapy for Welchol but not Ozempic, including UnitedHealthcare

Category

Ozempic

Welchol

At A Glance

RouteSC injection

FrequencyOnce weekly

ClassGLP-1 receptor agonist

RouteOral

FrequencyDaily

ClassBile acid sequestrant

Indications

Diabetes Mellitus, Non-Insulin-Dependent
Chronic Kidney Diseases

Familial hyperlipidemia
Familial hypercholesterolemia - heterozygous
Diabetes Mellitus, Non-Insulin-Dependent

Dosing

Diabetes Mellitus, Non-Insulin-Dependent Start 0.25 mg SC once weekly for 4 weeks, increase to 0.5 mg once weekly; escalate to 1 mg then 2 mg based on glycemic control (max 2 mg once weekly).

Chronic Kidney Diseases Start 0.25 mg SC once weekly for 4 weeks, increase to 0.5 mg once weekly; maintenance dose is 1 mg once weekly.

Familial hyperlipidemia, Familial hypercholesterolemia - heterozygous 3.75 grams daily; 6 tablets once daily or 3 tablets twice daily with a meal and liquid, or one packet oral suspension once daily with a meal.

Diabetes Mellitus, Non-Insulin-Dependent 3.75 grams daily; 6 tablets once daily or 3 tablets twice daily with a meal and liquid, or one packet oral suspension once daily with a meal.

Contraindications

Personal or family history of medullary thyroid carcinoma (MTC) or MEN 2
Serious hypersensitivity reaction to semaglutide or any excipient in Ozempic

Serum TG concentrations >500 mg/dL
History of hypertriglyceridemia-induced pancreatitis
History of bowel obstruction

Drug Interactions

943View drug interactions

861View drug interactions

Adverse Reactions

Most common (>=5%) Nausea, vomiting, diarrhea, abdominal pain, constipation

Serious Risk of thyroid C-cell tumors, acute pancreatitis, diabetic retinopathy complications, hypoglycemia with insulin secretagogues or insulin, acute kidney injury, severe gastrointestinal reactions, hypersensitivity reactions, acute gallbladder disease, pulmonary aspiration

Postmarketing Ileus, intestinal obstruction, severe constipation, fecal impaction, anaphylaxis, angioedema, rash, urticaria, cholecystitis, cholecystectomy, dysesthesia, headache, pulmonary aspiration, acute kidney injury, alopecia

Most common (>=2%) Constipation, dyspepsia, nausea, asthenia, pharyngitis, myalgia (primary hyperlipidemia); constipation, dyspepsia, nausea, hypertension, back pain (type 2 diabetes)

Serious Hypertriglyceridemia, pancreatitis, gastrointestinal obstruction, vitamin K and fat-soluble vitamin deficiencies

Postmarketing Bowel obstruction, dysphagia, esophageal obstruction, fecal impaction, pancreatitis, hypertriglyceridemia, increased transaminases

Pharmacology

Semaglutide is a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor, stimulating insulin secretion and lowering glucagon secretion in a glucose-dependent manner, with a minor delay in gastric emptying; prolonged half-life is achieved through albumin binding, which reduces renal clearance and protects against metabolic degradation.

Colesevelam hydrochloride is a non-absorbed bile acid sequestrant that binds bile acids in the intestine, depletes the bile acid pool, upregulates hepatic cholesterol 7-alpha-hydroxylase, increases LDL receptor expression, and thereby lowers serum LDL-C; the mechanism by which it improves glycemic control in type 2 diabetes is unknown.

View Full FDA Information

View full FDA information

Enter your patient's insuranceCheck specific coverage details for your patient.

Most Common Insurance

Anthem BCBS

Ozempic